Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

With Stelara's Star Set To Fade, J&J Assures Investors It Will Grow Anyway

Executive Summary

Johnson & Johnson investors are turning attention to 2023, when the company's top-selling drug is set to face biosimilar competition in the US for the first time.

You may also be interested in...



J&J Lays Out ‘Responsibly Cautious’ Growth Outlook

The company's 2023 revenue guidance calls for 4.5%-5.5% growth, taking into account ongoing macroeconomic uncertainty and inflationary pressures.

Pfizer Leads An Unusual Year For The Scrip 100

Pfizer catapulted back into the lead in the pharmaceutical rankings on the strength of COVID-19 revenues while BioNTech and Moderna both made the list for the first time.

J&J Adds Second Anti-BCMA Myeloma Therapy In US With Tecvayli Approval

Johnson & Johnson’s Janssen Pharmaceutical is building a multiple myeloma franchise beyond Darzalex, now with two BCMA-targeting therapies after CAR-T therapy Carvykti’s February approval.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC147216

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel